USPTO Patent Application: GOAT Inhibitors for Substance Use Disorder
Summary
The USPTO has published a patent application (US20260083736A1) for ghrelin O-acyl transferase (GOAT) inhibitors intended for the treatment of substance use disorder, particularly in patients with high impulsivity. The application details compounds of general formula I and their use in treating opioid or stimulant use disorders.
What changed
This document is a USPTO patent application (US20260083736A1) filed on September 22, 2025, for novel ghrelin O-acyl transferase (GOAT) inhibitors. These compounds are designed for the treatment of substance use disorders (SUD), with a specific focus on opioid use disorder (OUD) and stimulant use disorder (StimUD) in individuals exhibiting high impulsivity. The application outlines compounds of general formula I and their therapeutic applications.
As this is a patent application, it does not impose immediate compliance obligations on regulated entities. However, it signals potential future developments in pharmaceutical research and development for SUD treatments. Companies involved in drug discovery and development in this therapeutic area should be aware of emerging intellectual property in this space.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS FOR USE IN THE TREATMENT OF SUBSTANCE USE DISORDER IN PATIENTS WITH HIGH IMPULSIVITY
Application US20260083736A1 Kind: A1 Mar 26, 2026
Inventors
Stefan JUST, Hugo CRUCES SOLIS, Johann Faustus DU HOFFMANN, Jennifer Buenzle DWYER, Janet Rachel NICHOLSON, Katrin Hildegund PRELLER
Abstract
The present invention relates to compounds of general formula I, wherein the groups R1, R2 and n are defined herein, which are ghrelin O-acyl transferase (GOAT) inhibitors. The invention also relates to the use of compounds of formula (I) for treatment of substance use disorder (SUD,) in particular for use in the treatment of opioid use disorder (OUD) or stimulant use disorder (StimUD), in patients with high impulsivity.
CPC Classifications
A61K 31/506 A61K 31/437 A61K 31/444 A61K 31/497 A61K 31/5377 A61K 31/551
Filing Date
2025-09-22
Application No.
19335420
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.